Call for Abstract

International Congress on Drug Delivery, will be organized around the theme “Novelties in Drug Delivery, Formulation & Manifestation”

Drug Delivery Meet-Pharma-2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Drug Delivery Meet-Pharma-2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Pharmaceutical Conferences 2020 describes drug design is the method of inventing innovative medications. Drug design and Drug formulation defines the design of molecules that are corresponding in shape and charge to the bio molecular target with which they interact and therefore will bind to it. Generally, the drug is a tiny organic molecule which triggers or slows down the activity of a bio-molecule such as a protein which repeatedly results in a medicinal benefit to the patient. Discovery of drugs and Drug formulation is challenging. Various medications are invented by chance observations, the scientific examination of other medicines or by finding out the side effects of some other drugs. A methodical technique is significant screening observations where important drug targets are tested with thousands of various compounds to observe, whether conversations occur. Basically, Drug Formulation and drug design involves drug design of small molecules that are harmonizing in shape and charge to the biomolecular target to which they act together and consequently will bind to it

  • Track 1-1Drug targeting strategies
  • Track 1-2Factors influencing drug targeting
  • Track 1-3Drug design theory

Identifying drug objectives plays critical roles in designing new drugs, drug formulations and combating illnesses. Unfortunately, our cutting-edge expertise about drug objectives is a long way from comprehensive. Screening drug goals within the lab is an luxurious and time-ingesting technique. In the past decade, the accumulation of diverse forms of study of technology associated statistics makes it viable to expand computational strategies to are expecting drug targets. Non-communicable diseases together with most cancers, atherosclerosis and diabetes are answerable for maximum important social and health ache as hundreds of thousands of people are loss of life each year. Out of which, atherosclerosis is the main purpose of deaths international. The lipid abnormality is one of the maximum crucial modifiable threat elements for atherosclerosis. Both genetic and environmental additives are associated with the improvement of atherosclerotic plaques. Immune and inflammatory mediators have a complicated position within the initiation and development of atherosclerosis. Understanding of a majority of these processes will assist to invent a range of new biomarkers and novel remedy modalities concentrated on diverse cellular occasions in acute and chronic inflammation which can be accountable for atherosclerosis. Several biochemical pathways, receptors and enzymes are involved in the development of atherosclerosis that would be possible targets for improving strategies for disease diagnosis and management.


  • Track 2-1Micelles
  • Track 2-2Phonophoresis
  • Track 2-3Microspheres
  • Track 2-4Iontophoresis

The processes of designing a new drug by using bioinformatics implements have opened a new area of drug research and development. Computational techniques assist us in searching drug target and in Drug Formulation designing drug. Pharmaceutical Conferences 2020, Bioinformatics affects drug formulation and new drug design in the following drug design path. By using computational methods and the 3D structural information of the protein target, we are now able to scrutinize the detailed underlying molecular and atomic interactions involved in ligand: protein interactions and thus interpret experimental results in detail. The use of computers in drug formulation and drug discovery bears the additional advantage of delivering new drug candidates more rapidly and cost-efficiently. Computer-aided drug discovery has recently had important successes in drug formulation: new ligands have been predicted along with their receptor-bound structures and in several circumstances the achieved hit rates (ligands discovered per molecules tested) have been significantly greater than through experimental high-throughout screening. Strategies for CADD vary depending on the extent of structural and other information available regarding the target (enzyme/receptor) and the ligands.


  • Track 3-1Rational drug design
  • Track 3-2Recent approaches to drug targeting
  • Track 3-3Magnetic microparticles
  • Track 3-4Basic Drug designing

Size reduction is a fundamental unit operation having critical packages in Pharmaceutical Sciences, Drug Formulations. It enables in enhancing solubility and bioavailability, decreasing toxicity, enhancing release and providing better drug components possibilities for capsules. In maximum of the instances, size discount is limited to micron size variety, for instance, numerous pharmaceutical dosage forms like powder, emulsion, suspension etc. Drugs in the nano meter size variety beautify overall performance in an expansion of dosage paperwork. Major benefits of nanosizing include (i) increased surface area, (ii) enhanced solubility, (iii) increased rate of dissolution, (iv) increased oral bioavailability, (v) more rapid onset of therapeutic action, (vi) less amount of dose required, (vii) decreased fed/fasted variability, and (viii) decreased patient-to-patient variability.


  • Track 4-1Nano-drugs
  • Track 4-2Nanobiomaterials and biopharmaceuticals
  • Track 4-3Nanotechnology and clinical applications
  • Track 4-4Nanotechnology in medicine and drug delivery imaging

Regulatory Affairs contributes essentially to the overall success of drug development, both at early pre-advertising and marketing tiers and at all times post-advertising and marketing. The pharmaceutical enterprise deals with more and more exciting drug candidates, all of which necessitate the involvement of the Regulatory Affairs’ branch. Regulatory Affairs specialists can play a key position in guiding drug formulations method in an increasingly more global surroundings. But additionally they play an essential operational function, for example, by way of thinking about the first-class approaches to comply with and allowing dependent interplay with regulatory authorities. Regulatory Affairs is driven by top science and for that reason nothing stays static.

  • Track 5-1Pharmacoepidemiology of drug shortages
  • Track 5-2Dosage regimen, drug toxicity and drug safety measures
  • Track 5-3Drug Compliance Programs

The global market for Business Development of Drug Delivery Technology in 2010 was $131.6 billion and is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016. The U.S constituted approximately 59% of the total drug delivery market in 2010 and was $78 billion. It is forecast to reach nearly $103 billion in 2016 at a CAGR of 4.7%. Europe contributed about 27% of the total drug delivery market in 2010 and was $36 billion and is expected to grow to $49 billion by 2016 at a CAGR of 5.6% in 2013, Drug Delivery Global market reached $150.3 billion, according to BCC research. This was an increase from $142 billion the previous year. Given its predicted annual growth the market represents a considerable business opportunity, which has been reflected in increasing number of drug delivery specialists. Consistent quality and competitive costs of product improves Production performance and continuity of supply and Product and technology auditing and due diligence with minimizing Regulatory Issues, drug formulation, quality control, and business development Business opportunities in drug delivery.


  • Track 6-1Post- marketing surveillance
  • Track 6-2Pharmaceutical Marketing
  • Track 6-3Good manufacturing practices
  • Track 6-4Pharma Manufacturing

Bioequivalence research are achieved for both Early & past due Clinical Trial formulations, Drug formulations used in medical trials and stability studies, if exceptional Clinical trial formulations and to-be-advertised drug product on the subject of value and productivity metrics, it’s often said that what receives measured gets performed. Bioequivalence is determined primarily based on the bioavailability of the innovator remedy as opposed to the standard medication. The outline for bioequivalence have a look at includes the business enterprise of check and reference gadgets on two activities to volunteer subjects, with each corporation isolated by a washout period. This Study involves parameters on (Cmax) and (AUC), Statistical evaluation.

Assessment of the bioequivalence of generic versions of certain reference drugs is complicated by the presence of endogenous levels of said compounds which cannot be distinguished from externally derived compound levels following drug administration. If unaccounted for, the presence of endogenous compound biases towards equivalence in bioequivalence studies of these drugs. Bioequivalence assessments may be complicated further as disposition of the exogenous analogue can be subject to various endogenous processes resulting in nonlinear pharmacokinetics. To overcome these inherent biases a number of different strategies have been employed.


  • Track 7-1In vivo & In vitro drug studies
  • Track 7-2Accelerated stability studies
  • Track 7-3HPLC to monitor β-lactam plasma
  • Track 7-4Cationic prodrugs as dual gene reagents

Pharmaceutical engineering is a branch of pharmaceutical technology and science that involves improvement and production of products, techniques, and additives within the pharmaceuticals industry (i.e. drugs & biologics). While developing pharmaceutical merchandise includes many interrelated disciplines (e.g. medicinal chemists, analytical chemists, clinicians/pharmacologists, pharmacists, chemical engineers, biomedical engineers, etc.), the precise subfield of "pharmaceutical engineering" has most effective emerged recently as a divergent engineering discipline. This now brings the trouble-solving standards and quantitative education of engineering to complement the opposite scientific fields already worried in drug formulation.


  • Track 8-1Engineering of Pharmaceutical Nanosystems
  • Track 8-2Challenges to Pharmaceutical Nanotechnology
  • Track 8-3Pharmaceutical technology

Development of a new medicine takes nearly 10-15 years and on average and costs an average of $2.6 billion. In discovery procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes   three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.


  • Track 9-1Agricultural BiotechnologyBio Informatics Characterization of Pharmaceutical Nanotools
  • Track 9-2Applications of Pharmaceutical Nanotools
  • Track 9-3Pharmaceutical jurisprudence
  • Track 9-4Agricultural BiotechnologyBio Informatics
  • Track 9-5Dosage regimen, drug toxicity and drug safety measures


Pharmaceutical formulations vary on the route of administration. Eternal formulations prolong the action of duration of drug. Eternal formulation includes tablet, capsule and sustained release dosage forms. Parenteral formulation impacts both the safety and efficacy of drug. The effect of the dosage form depends on the route of administration. A low medication load may cause homogeneity issues. A high medication load may posture stream issues or require extensive containers if the compound has a low mass thickness.




  • Track 10-1Preformulation in drug discovery
  • Track 10-2Preformulation in drug development
  • Track 10-3Drug formulation considerations
  • Track 10-4Formulation types

Medication are used to prevent and illness. Depending upon their site of action and safety and efficacy of drug drugs can be administered through a variety like oral, parenteral, Transdermal, Intradermal etc.. While administering a drug we have to consider the possible side effects and dangerous reactions also. The Dosage of the drug has to be carefully determined. In US, it has been estimated that 80 per cent of active ingredients and 40 per cent of the final drug products are imported. Medicine slant and bolster significance have been surveyed by taking a gander at the self-association of no less than two drugs open under various trial conditions, including choice procedure, dynamic extent fortress timetables, and chain stronghold logbooks.


  • Track 11-1Implantable Drug Delivery System
  • Track 11-2Pediatric Drug Delivery systems
  • Track 11-3Traditional Delivery Routes

These are changing the world of drug delivery and preventing the patients from continuous bulk ambulatory devices. Wearable drug delivery device delivers insulin to the wearer.  These are developed for dosing a range of drugs such as hormones, analgesics, anti-hypertensives. Large doses 5ml to 50 ml can be comfortably be self-administered by the patient at home by using the Wearable Drug Delivery devices. The life cycle of the product can also be increases. Wearable technology speeds the Formulation and development.

The annual growth rate is expected to reach USD $824 bn by 2025. The size of the market opportunity for LVI devices alone has been estimated at $8.1 billion by 2025, with over 50% of this driven by devices to deliver drugs for cancer and related conditions.


  • Track 12-1Drug-Device compatibility
  • Track 12-2Pharmaceutical Nanotechnology
  • Track 12-3Sustained delivery